Litigation

Recent Posts

Russell Budd Announces Opening Of Baron & Budd P.C. Office In Miami
Posted on 10 Aug 2010 by LexisNexis Litigation Resource Community Staff

MIAMI - Russell Budd has announced the opening of plaintiff's law firm Baron & Budd, P.C. 's new office in Miami. The new office will offer its services to individuals and businesses with environmental issues as well as those victimized... Read More

$2M N.J. Accutane Verdict Reversed, 2 Defense Verdicts Affirmed On Appeal
Posted on 4 Aug 2014 by Tom Moylan

TRENTON, N.J. — (Mealey’s) A New Jersey appeals panel on Aug. 4 vacated a $2,125,617 Accutane bowel injury verdict and affirmed defense verdicts in two other cases tried at the same time ( Gillian Gaghan v. Hoffman-La Roche Inc., et al. ,... Read More

Pennsylvania Appeals Court Affirms $10M Children’s Motrin TEN Injury Verdict
Posted on 23 Jul 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania appeals court panel on July 22 affirmed a $10 million Children’s Motrin verdict for a girl who suffered toxic epidermal necrolysis (TEN) after being given the over-the-counter pain/fever reducer... Read More

$2.36B Glaxo Charge Covers Avandia, Paxil Litigation, Other Legal Costs
Posted on 15 Jul 2010 by Tom Moylan

LONDON - (Mealey's) GlaxoSmithKline PLC (GSK) on July 15 said it expects to take a $2.36 billion charge against earnings to settle several legal issues, including settling "the substantial majority" of Avandia product liability cases and... Read More

Pennsylvania State Court Jury Awards $2.5 Million In Risperdal Gynecomastia Trial
Posted on 24 Feb 2015 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Feb. 24 awarded $2.5 million to the family of a man who claimed that the atypical antipsychotic drug Risperdal caused gynecomastia, or enlarged male breasts ( P.P., et al. v. Ortho... Read More

New Jersey Jury Awards $1.58M In Retrial Of Accutane Bowel Injury Case
Posted on 11 Mar 2014 by Tom Moylan

ATLANTIC CITY, N.J. — (Mealey’s) A New Jersey state court jury on March 11 found that Hoffman-La Roche failed to adequately warn that its former acne drug Accutane could cause ulcerative colitis and awarded the plaintiff $1,587,928 for past... Read More

Norton Rose Fulbright: FDA’s Expanded Oversight Of ‘High-risk’ Diagnostic Devices
Posted on 7 Aug 2014 by Norton Rose Fulbright

By Cori Annapolen Goldberg and Lidia Niecko-Najjum In efforts to ensure that in vitro diagnostic devices 1 provide accurate, consistent and reliable results, the US Food and Drug Administration ("FDA" or "the Agency") 1) issued... Read More

Pennsylvania State Court Jury Awards Plaintiff $2 Million In Actos Bladder Cancer Case
Posted on 6 Oct 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) A Pennsylvania state court jury on Oct. 3 awarded an Actos bladder cancer patient $2.05 million in economic and noneconomic damages but declined to award punitive damages ( Frances Wisniewski v. Takeda Pharmaceuticals... Read More

Defense Verdict Returned In Purported 1st Zoloft Birth Defect Trial
Posted on 20 Apr 2015 by Tom Moylan

ST. LOUIS — (Mealey’s) A Missouri state court jury on April 17 returned a defense verdict in a Zoloft birth defect trial said by the parties to be the first trial of its kind in the nation ( Kristyn Pesante, et al. v. Pfizer, Inc. , No. 122... Read More

Janssen Settles Some Pa. Topamax Birth Defect Cases, Will Appeal $3M Verdict
Posted on 11 Mar 2014 by Tom Moylan

PHILADELPHIA — (Mealey’s) Topamax manufacturer Janssen Pharmaceuticals on March 10 said it will appeal a $3 million March 7 birth defect verdict in the Philadelphia County Common Pleas Court even though it reached an agreement to resolve a... Read More

Ballard Spahr LLP: Pharmaceutical Companies Get Off-Label Marketing Victory
Posted on 18 Aug 2015 by Ballard Spahr LLP

. . . A federal judge ruled that the Food and Drug Administration (FDA) cannot prohibit a pharmaceutical company from marketing its drugs for off-label uses if its claims are truthful and not misleading. This ruling, while not precedential, alters the... Read More

U.S. High Court Denies Review Of Last Pending Appeal Of Generic Label-Update Claim
Posted on 18 May 2015 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) The U.S. Supreme Court on May 18 denied review in the last pending “failure-to-update-warnings” preemption appeal by generic drug manufacturers ( Teva Pharmaceuticals USA, Inc., et al. v. Paul E. Hassett... Read More

Another Specialty Pharmacy Settles Exjade False Claims Allegations For $45 Million
Posted on 1 May 2015 by Tom Moylan

NEW YORK —(Mealey’s) Specialty pharmacy Accredo Health Group Inc. on April 30 agreed to pay $45 million to settle a whistle-blower’s allegations that its efforts to push prescriptions for the iron chelation drug Exjade resulted in false... Read More

Arkansas High Court Reverses $1.2B Risperdal Verdict For State Law Violations
Posted on 21 Mar 2014 by Tom Moylan

LITTLE ROCK, Ark. — (Mealey’s) In a 4-3 decision, the Arkansas Supreme Court on March 20 reversed a $1.2 billion verdict against Janssen Pharmaceuticals for violating state law in its marketing of the antipsychotic drug Risperdal ( Ortho-McNeil... Read More